Authors: Joey Rehkopf, Nikolas Richter, Maud Brijs, Kristof Theys, Malte Glüsen, Matthias P. Schönermark Monday 10th Nov 2025 Poster Presentation: […]
In this comprehensive report, Kintiga explores the strategic implications of this legislation for market access in Germany. Why now? Pharmaceutical
EU HTA: One HTA Regulation for All The strategic perspective on EU HTA from the Kintiga team For a deeper
Authors: Kielhorn-Schönermark, H., Zavatta, E., Sake, S., Hantke, I. Summary: Market access in Germany is and remains one of the
Effects on Benefit Assessment and Price Development Authors: Sake SM, Martyniszyn-Eiben A, Zavatta E, Glüsen M, Berger I, Schönermark M
Chances and Risks of Benefit Re-Assessments Due to New Scientific Evidence in Germany Authors: Schwerdtfeger V, Hantke I, Schönermark M
PROM Are of Profound Importance for the Success of Health Technology Assessments in Oncologic Indications in Germany Authors: Brand D,
Outcomes of Benefit Assessments of Orphan Drugs Without Orphan Designation in Germany Authors: Frick L, Qiu Z, Schönermark M. Objectives:
Author: Dr. Matthias Schönermark Insightful discussion with Prof. Dr. Matthias P. Schönermark, and Oznur Seyhun, Partner & Anchorwoman at Market
